Sleepiness and fatigue are two distinct symptoms that negatively affect daily functioning and are commonly seen in both clinical settings and general populations. While there are objective and subjective instruments to measure sleepiness, only rating scales are available for measuring fatigue. The top three commonly used rating scales are the FSS, CFS, and FIS. Accurately assessing sleepiness and fatigue is crucial for clinical understanding of patients and research purposes. Further research is needed to explore potential mechanisms underlying the measurements of sleepiness and fatigue, as well as to establish objective assessing instruments to evaluate fatigue and clarify the relationship between objective and subjective assessments of sleepiness.

A new study has found that common medications for relieving fatigue in patients with multiple sclerosis, including methylphenidate, modafinil, and amantadine, do not work effectively and can cause side effects. The double-blind trial was conducted at two academic multiple sclerosis centres in the US and found the three medications were not superior to placebos in improving multiple sclerosis fatigue. The findings showed that patients reported more frequent adverse effects while on the medications than while on placebos. The study, which analysed 136 participants, does not support the use of the three drugs for treating multiple sclerosis fatigue. Campaigners noted that the results underscored the need for fresh approaches to alleviate related symptoms.

A study was conducted to determine the prevalence of sleep problems and fatigue in children with chronic kidney disease (CKD), and to assess the extent of their association with measured glomerular filtration rate (mGFR) and health-related quality of life (HRQOL). The study found that symptoms of sleepiness and fatigue are prevalent in children with CKD. Additionally, the study found that children with lower mGFR values experienced more severe symptoms of sleepiness and fatigue. The study highlights the importance of monitoring sleep and fatigue symptoms in children with CKD to improve their quality of life. Healthcare professionals should assess these symptoms and make appropriate interventions. Conclusion: CKD is a serious condition that can cause sleepiness and fatigue in children. Healthcare professionals should monitor and assess these symptoms to improve the quality of life of children with CKD. Interventions may be necessary to address these symptoms and improve overall health outcomes. The study is a significant contribution to the current body of knowledge and further research is necessary to determine the most effective interventions.